AxoGen

AxoGen is a developer of surgical solutions, including human tissue grafts, based in Alachua, Florida.[1] Axogen products are designed to remedy peripheral nerve damage.[2][3] In 2013 the company raised $18 million in its initial public offering (IPO).[4] AxoGen uses a cell graft technology AVANCE to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes.[5] The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. AxoGen is part of the Sid Martin Biotechnology Incubator.

AxoGen
NASDAQ: AXGN
Russell 2000 Component
Headquarters
United States 

As of 2019, AxoGen was the only commercially available allograft approved by the Food and Drug Administration (FDA) for clinical use.

See also

References
  1. Inc, Axogen (2020-05-06). "Axogen, Inc. Reports First Quarter 2020 Financial Results". GlobeNewswire News Room. Retrieved 2020-06-03.
  2. Graft Helps Nerves Regrow; More Patients Avoid Amputation Through Technique Based on Cadaver Implant December 26, 2012 by Melinda Beck
  3. Nerve repair using grafts from cadavers; SURGERY Grafts from cadavers offer alternative, providing more choice, less traumaby Drew Joseph February 19, 2013 San Francisco Chronicle (SFGate)
  4. [Alachua] Business Briefs November 2013 Florida Trend Magazine
  5. www.bloomberg.com https://www.bloomberg.com/profile/company/AXGN:US. Retrieved 2020-06-03. Missing or empty |title= (help)
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.